Plain-English translation of NCT05588492 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
After a kidney transplant, your immune system is weakened by medications that prevent rejection, which puts you at higher risk of developing active tuberculosis from an old, dormant infection. This study is testing whether a shorter three-month course of rifamycin-containing regimens—medications that combine rifapentine or rifampicin with isoniazid—can safely prevent TB in transplant patients, since most research on these medications has been done in people without transplants.
Kidney transplant recipients are at much higher risk of developing active, life-threatening TB from latent infection, but doctors aren't sure whether the newer, shorter TB prevention treatments work safely in this group, especially since these medications can interact with the anti-rejection drugs transplant patients take.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be assigned to receive either a three-month course of the rifamycin-containing medication or an alternative TB prevention regimen. The study team will monitor you closely for any side effects, check whether the medication interacts with your anti-rejection drugs, and track whether you complete the full treatment. You'll have follow-up visits and tests to see how well the treatment works at preventing active TB.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Taiwan